1. Home
  2. SLE vs BCDA Comparison

SLE vs BCDA Comparison

Compare SLE & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Super League Enterprise Inc.

SLE

Super League Enterprise Inc.

HOLD

Current Price

$4.81

Market Cap

177.4M

ML Signal

HOLD

Logo BioCardia Inc.

BCDA

BioCardia Inc.

HOLD

Current Price

$1.12

Market Cap

14.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLE
BCDA
Founded
2014
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
177.4M
14.1M
IPO Year
2019
2009

Fundamental Metrics

Financial Performance
Metric
SLE
BCDA
Price
$4.81
$1.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$60.00
$25.00
AVG Volume (30 Days)
2.1M
162.2K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,064,000.00
$479,000.00
Revenue This Year
$24.86
N/A
Revenue Next Year
$49.77
N/A
P/E Ratio
N/A
N/A
Revenue Growth
90.41
N/A
52 Week Low
$0.48
$0.75
52 Week High
$11.43
$2.27

Technical Indicators

Market Signals
Indicator
SLE
BCDA
Relative Strength Index (RSI) 59.76 56.90
Support Level $3.27 $0.78
Resistance Level $5.24 $1.26
Average True Range (ATR) 0.43 0.06
MACD 0.05 -0.00
Stochastic Oscillator 68.29 50.73

Price Performance

Historical Comparison
SLE
BCDA

About SLE Super League Enterprise Inc.

Super League Enterprise Inc connects brands with the gaming population of around 3.5 billion through advertising and branded content programs across gaming and digital media platforms. The Company generates revenue by delivering these programs through proprietary interactive formats, creator content, immersive experiences, data-driven insights, and strategic campaign services designed to improve marketing performance. By translating player behavior into actionable intelligence, Super League serves as a trusted partner helping brands reach and influence consumers who play video games. With a deep understanding of this engaged yet under-monetized audience, it is positioned to capture an increasing share of brand advertising spend as the market evolves.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: